Oncosec needed to over deliver the interim results to get a much better reaction regarding share price. If the combo trial is ammended to finish enrollment with only patients that have already 100% failed keytruda monotherapy and we still get the 40% ORR they announced today that will hold a lot more weight to the final data next year. That should set us up nicely for the registration trial. This is going to take patience for long holders. Short holders will sell here.
News 
Market Data 
Discover 
AI
